Qiagen announced it has received an emergency use authorization (EUA) from the U.S. Food and Drug Administration for its QIAreach SARS-CoV-2 Antigen Test, a rapid portable test that the company said can analyze over 30 samples per hour for the SARS-CoV-2 antigen.
The company touted its test, developed in collaboration with Ellume, as providing digital results in two to 15 minutes. It also uses Qiagen's Underwriters Laboratories (UL)-certified eHub, a portable reader with backup battery power that can be operated remotely from the main power for up to eight hours.
